Evaluation of Allopurinoleffect on Plasma Level of Cardiac Troponin-IandCreatine Kinase- MB in acute ischemic heart disease (ACS)

Abstract

Background:Acute myocardial infarction is one of leading causes of death. It appears that there is asignificant relationship between CK-MB and cTnI elevation following PCI and cardiovascular mortality and morbidity.

Aim: Due to the potential effect of allopurinol on ischemic heart disease, this study was performed to evaluate the cardioprotective effect of allopurinol in myocardial infarction patients with NSTEMI.

Methods: A randomized clinical trial including a total number of 107 patients diagnosed with NSTEMI wasperformed. Intervention group (n=50)received 600mg Allopurinol orally in two divided doses on the first day and then 300 mg on the second and third days plus the standard treatment, while control group (n=50) only received the standard treatment(aspirin 325 mg, clopidogrel 300 mg, weight-adjusted intravenous heparin with a target activated clotting time 250-350 seconds).To assess myocardial damage, serum concentrations of troponin I was measured before, 8,16,24 and32 hours after procedure.

Result: There were no significant differences in troponin I levels at base(p=0.845), 8 (p=0.499) , 16 (p=0.729), 24 (p=0.178)and 32 hours(P=0.722) between Allopurinol and control group.

Conclusion: This study did not support the potential cardioprotective effect of pre-treatment with Allopurinol against myocardial injury in patients with NSTEMI. However, a non-significant trend toward the potential benefit of Allopurinol was observed in the present study.